

Consensus statement of the Paediatric Anaesthesiology and Intensive Therapy Section of the Polish Society of Anaesthesiology and Intensive Therapy on the use of VV ECMO in paediatric patients for the treatment of acute respiratory failure

Jowita Rosada-Kurasińska¹, Alicja Bartkowska-Śniatkowska¹, Marzena Zielińska^{2,3}, Małgorzata Mikaszewska-Sokolewicz⁴, Bartłomiej Kociński⁵, Remigiusz Jaśkiewicz⁶, Izabela Pagowska-Klimek⁷

¹Department of Paediatric Anaesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland

²Department of Anaesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland

³Department of Paediatric Anaesthesiology and Intensive Therapy, Jan Mikulicz-Radecki University Hospital in Wroclaw, Wroclaw, Poland

⁴Department of Anaesthesiology and Intensive Care, Children's Memorial Health Institute, Warsaw, Poland

⁵Department of Paediatric Cardiac Surgery, Poznan University of Medical Sciences, Poznan, Poland

⁶Department of Anaesthesiology and Intensive Care Medicine, Children's University Hospital of Cracow, Cracow, Poland

⁷Department of Paediatric Anaesthesiology and Intensive Therapy, Medical University of Warsaw, Warsaw, Poland

Abstract

Extracorporeal membrane oxygenation (ECMO) is widely used in paediatric cardiac surgery units. Over recent years, interest in ECMO has grown among anaesthesiologists working in paediatric intensive care units. The indication for ECMO therapy is respiratory or cardiopulmonary failure in which, despite high inspired oxygen concentrations, advanced ventilator strategies and optimisation of the patient's condition, persistent hypoxaemia and hypercapnia carry a risk of further deterioration and death. This consensus statement of Paediatric Anaesthesiology and Intensive Therapy Section of the Polish Society of Anaesthesiology and Intensive Therapy provides recommendations on the use of veno-venous ECMO in paediatric patients in Poland, with the aim of improving outcomes in severe respiratory failure and facilitating appropriate selection of patients for ECMO support.

Key words: extracorporeal membrane oxygenation (ECMO), veno-venous ECMO, acute respiratory failure, paediatric acute respiratory distress syndrome (PARDS), children, anticoagulation, patient transfer, consensus statement.

Anaesthesiol Intensive Ther 2026; 58: e137–e155

Received: 12.02.2026, accepted: 08.05.2026

CORRESPONDING AUTHOR:

Jowita Rosada-Kurasińska, PhD, Department of Paediatric Anaesthesiology and Intensive Therapy, Poznan University of Medical Sciences, 27/33 Szpitalna St., 60-572 Poznan, Poland, e-mail: jrosada@ump.edu.pl

Extracorporeal blood oxygenation techniques are widely used in paediatric cardiac surgery units. Over the past several years, interest in these methods has grown among anaesthesiologists working in paediatric intensive care units. The term extracorporeal life support (ECLS) refers broadly to extracorporeal support of cardiopulmonary function using a circuit containing at least a pump and a membrane lung. Systems used for blood oxygenation and/or circulatory support are termed extracorporeal membrane oxygenation (ECMO), whereas systems aimed primarily at carbon dioxide removal are called extracorporeal carbon dioxide removal (ECCO₂R) [1].

Current nomenclature distinguishes four types of ECMO support: venoarterial (VA) for cardiac failure,

venoarteriovenous (VAV) for combined cardiac and respiratory failure, venovenous (VV) for respiratory failure, and venopulmonary (VP) for right ventricular failure with respiratory failure [1]. VV ECMO is used in conditions involving potentially reversible severe pulmonary dysfunction in which mechanical ventilation cannot achieve adequate gas exchange. VA ECMO is used in potentially reversible or irreversible cardiac failure [2].

The indication for VV ECMO is respiratory failure in which, despite high inspired oxygen concentrations, advanced ventilator strategies and other optimisation measures such as prone positioning, persistent hypoxaemia and hypercapnia threaten further deterioration and death.

The method has been in use since the 1970s, when Dr Robert Bartlett first described ECMO in neonates [3]. The most common indications at that time were meconium aspiration syndrome (MAS), congenital diaphragmatic hernia, pulmonary hypertension, sepsis and respiratory distress syndrome (RDS). The introduction of surfactant, high-frequency oscillatory ventilation (HFOV) and inhaled nitric oxide (iNO) later reduced the need for ECMO in this population.

ECMO does not treat the lungs themselves; it offers the patient a chance of survival when pulmonary function is so impaired that arterial oxygenation and/or CO₂ elimination cannot be sustained. VV ECMO supports the patient when mechanical ventilation is inadequate or harmful, provides excellent gas exchange and at the same time minimises the risks associated with mechanical ventilation. ECMO should therefore be considered in patients with a recognised or suspected reversible pathology in whom the technique carries less risk than withholding it. Decisions must take into account the patient's history and the centre's experience with this therapy. When assessing the need for ECMO, the direction and rate of change in gas-exchange parameters under advanced ventilator strategies, prone positioning and general optimisation should be evaluated; delaying ECMO reduces the chance of survival.

In a critically ill patient being considered for ECMO, time is often insufficient to weigh many factors, including projected mortality with and without ECMO, the direction and pace of clinical change, reversibility of the underlying disease, eligibility for transplantation, and quality of life after therapy. Although these decisions often have to be made without all of the relevant data, the rationale for ECMO is best defined before vascular cannulation. The aim is a shared understanding of both the goals and the criteria among all members of the ECMO team and the patient's surrogate decision-makers (parents or legal guardians). This multidisciplinary approach, with family involvement, is central to avoiding situations in which ECMO becomes an endpoint rather than the intended bridging therapy. The key question is whether ECMO will serve as a bridge to recovery or transplantation, or rather as a "bridge to nowhere" [4].

The authors hope that this statement of the Section of Paediatric Anaesthesiology and Intensive Therapy of the Polish Society of Anaesthesiology and Intensive Therapy on the use of VV ECMO in the paediatric population in Poland will improve outcomes in severe respiratory failure: by increasing access to the therapy for patients who meet the indications, and by identifying those for whom ECMO will not be helpful.

PAEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME

Paediatric acute respiratory distress syndrome (PARDS) was first defined in 2015 by an expert group convened at the Pediatric Acute Lung Injury Consensus Conference (PALICC) [5]. That conference established the first definition of ARDS applied specifically to paediatric patients and formally adopted the term PARDS. Recommendations were also issued on treatment, ventilation strategies and adjunctive therapies. The 27 experts from 8 countries produced 132 strong recommendations and 19 weak ones.

In 2023, the second PALICC conference (PALICC-2) published updated guidelines developed by 52 experts from 15 countries working in 11 groups across 11 PARDS-related areas [6]. The first group addressed the definition, incidence and epidemiology of PARDS; subsequent groups covered pathophysiology, severity and risk assessment. A separate group analysed ventilation methods and monitoring, and another formulated recommendations on extracorporeal support, including ECMO. Notably, recommendations were also formulated for countries and regions with limited resources. The work produced 146 recommendations and statements: 32 clinical practice recommendations and 112 consensus-based statements; of the latter, 18 concerned the PARDS definition, 55 "good practice", 7 policy and 32 research questions. All recommendations and statements achieved more than 80% agreement [6].

Definition of PARDS

The diagnostic criteria for PARDS, taking into account age (birth to under 18 years), the time of onset of hypoxaemia and radiological changes, their nature from the onset of illness, oxygenation parameters and severity stratification, are summarised in Table 1.

The definition also recognises two special groups: children with cyanotic congenital heart disease and those with chronic lung disease.

The paediatric definition differs from the adult ARDS definition by allowing oxygenation in children to be assessed using arterial saturation (SpO₂) alone, via the oxygen saturation index (OSI). An OSI above 5 in invasively ventilated children, like an oxygenation index (OI) above 4, is one of the criteria for diagnosing PARDS. In non-invasively ventilated children, a ratio of peripheral oxygen saturation to fraction of inspired oxygen (SpO₂/FiO₂) below 250, or a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) below 300, raises suspicion of PARDS.

The use of saturation values for both diagnosis and severity stratification reflects the fact that arterial cannulation is considerably more difficult in

TABLE 1. Definition of paediatric acute respiratory distress syndrome (PARDS)

Age	Excludes children with respiratory problems related to perinatal lung disease
Timing	Within 7 days of a recognised insult
Origin of oedema	Respiratory failure not fully explained by cardiac failure or fluid overload alone
Imaging	New infiltrative changes (unilateral or bilateral) consistent with interstitial pneumonitis, not attributable to atelectasis or pleural effusion
Oxygenation, NIV (full face mask with CPAP or PEEP ≥ 5 cmH ₂ O)	$\text{PaO}_2/\text{FiO}_2 \leq 300$ or $\text{SpO}_2/\text{FiO}_2 \leq 250$
Oxygenation, IMV	$\text{OI} \geq 4$ or $\text{OSI} \geq 5$
Severity, mild/moderate (assessed 4 hours after the initial PARDS diagnosis)	IMV-PARDS: $\text{OI} < 16$ or $\text{OSI} < 12$, NIV-PARDS: $\text{PaO}_2/\text{FiO}_2 > 100$
Severity, severe (assessed 4 hours after the initial PARDS diagnosis)	$\text{OI} \geq 16$ or $\text{OSI} \geq 12$, $\text{PaO}_2/\text{FiO}_2 \leq 100$ or $\text{SpO}_2/\text{FiO}_2 \leq 150$
Cyanotic congenital heart disease	Criteria as above plus an acute deterioration in oxygenation not attributable to the cardiac lesion
Chronic lung disease	Criteria as above combined with an acute deterioration in oxygenation relative to baseline

CPAP – continuous positive airway pressure, IMV – invasive mechanical ventilation, MAP – mean airway pressure (cmH₂O), NIV – non-invasive mechanical ventilation, OI – oxygenation index ($[\text{MAP} \times \text{FiO}_2 \times 100]/\text{PaO}_2$), OSI – oxygen saturation index ($[\text{MAP} \times \text{FiO}_2 \times 100]/\text{SpO}_2$), $\text{PaO}_2/\text{FiO}_2$ – ratio of arterial oxygen partial pressure to inspired oxygen fraction, PEEP – positive end-expiratory pressure

a small child than in an adult, and even harder to maintain over time. Efforts to limit invasive procedures, particularly in infants, are also relevant [6, 7].

Beyond the criteria for PARDS itself, criteria have been defined for two further groups of children with acute respiratory failure: those with possible PARDS and those at risk of developing PARDS.

The first group includes children on nasal respiratory support – nasal continuous positive airway pressure (nCPAP) or nasal bilevel positive airway pressure (nBIPAP) – or high-flow nasal cannula (HFNC) at flows ≥ 1.5 L kg⁻¹ min⁻¹ or 30 L min⁻¹ with $\text{PaO}_2/\text{FiO}_2 \leq 300$ or $\text{SpO}_2/\text{FiO}_2 \leq 250$.

The at-risk group includes children who require passive oxygen therapy to maintain saturations $\geq 88\%$ but do not meet the criteria for PARDS.

Respiratory management in PARDS

1. In children who do not meet full PARDS criteria but are classified as having possible PARDS or as being at risk, non-invasive respiratory support with HFNC, nCPAP or nBiLevel may be used.
2. The duration of these therapies is limited. If no improvement occurs within 0–6 hours, or if the child deteriorates despite these measures, endotracheal intubation and invasive mechanical ventilation should be initiated.
3. Non-invasive ventilation should also be considered in immunosuppressed children because of the higher risk of complications associated with invasive ventilation.
4. No single ventilator mode is recommended for PARDS. Evidence is lacking that controlled modes, pressure- or volume-triggered supported modes, or neurally adjusted ventilatory assist are superior to one another.

5. It is, however, a strong clinical recommendation that children with PARDS be ventilated according to a lung-protective strategy (LPS).

6. An LPS uses tidal volumes (TV) of 6–8 mL kg⁻¹. Lower volumes (4–6 mL kg⁻¹) are recommended only when this is the only way to keep peak inspiratory pressure (PIP) and plateau pressure (P_{plat}) at acceptable levels ($P_{\text{plat}} \leq 28$ cmH₂O, or ≤ 32 cmH₂O when chest-wall compliance is reduced) [6, 7].
7. Driving pressure ($\text{DP} = P_{\text{plat}} - \text{PEEP}$) is suggested to remain below 15 cmH₂O and should be monitored.
8. PEEP should be at least 5 cmH₂O; optimally, the PEEP/ FiO_2 table from the ARDS Network protocol should be used.
9. PEEP should be titrated to haemodynamics, lung compliance and the $\text{PaO}_2/\text{FiO}_2$ ratio measured under static conditions. When adjusting PEEP, the recommended P_{plat} and/or DP limits must be maintained.

The strategies above aim to limit ventilator-induced lung injury (VILI). Additional recommendations:

- In mild and moderate PARDS, the target SpO_2 is 92–97%; in severe PARDS, above 92%.
- In mild and moderate PARDS, SpO_2 below 88% and above 97% should be avoided. In severe PARDS, when saturation remains below 92%, central venous saturation monitoring is recommended.
- Permissive hypercapnia is acceptable provided pH is ≥ 7.2 , when necessary to maintain the recommended upper limits of P_{plat} , DP and TV.
- Routine sodium bicarbonate is not recommended.
- If conventional mechanical ventilation fails, unconventional modes including HFOV should be considered.

- When conventional ventilation fails in a child with PARDS from a potentially reversible cause and an LPS does not provide adequate gas exchange, ECMO should be considered [8, 9].
- No precise criteria identify which PARDS patients will benefit most from ECMO.
- The decision to initiate ECMO in a child with PARDS should be based on a detailed assessment of the disease course and clinical condition by an expert team.
- Assessment should be repeated over short intervals rather than performed once.
- In children with preserved cardiac function, VV ECMO is the technique of choice.
- ECMO should be conducted in centres experienced in this therapy, such as referral centres.
- Centres providing ECMO should report all data to the Extracorporeal Life Support Organization (ELSO).
- During ECMO in children with PARDS, PaO₂ should be kept within the normal range and hyperoxaemia avoided.
- Once a child with PARDS is on ECMO, PCO₂ should be reduced gradually.
- Mechanical ventilation in PARDS patients on ECMO should follow an LPS.
- All children who survive ECMO should undergo assessment of short- and long-term neurodevelopmental outcome [6, 9].
- No recommendation can be made on the use of ECCO₂R in children with PARDS [6].

INDICATIONS AND CONTRAINDICATIONS IN INFANTS AND CHILDREN (> 30 DAYS < 18 YEARS)

In the paediatric population, VV ECMO is indicated in severe hypoxaemic PARDS, although evidence specific to children remains limited. Data published by the International ELSO Registry in April 2021 demonstrate the effectiveness of VV ECMO in 60–80% of paediatric patients with viral (71%), bacterial (74%), pneumocystis (80%), aspiration (70%) and post-traumatic (70%) pneumonia.

VV ECMO has two principal advantages: it provides support when mechanical ventilation is inadequate, and it limits the harmful effects of mechanical ventilation itself and the risks that accompany it. The underlying disease is not the sole criterion for inclusion in or exclusion from ECLS; current gas exchange relative to current ventilator settings, the rate of change and the effectiveness of other rescue therapies (e.g. prone positioning, HFOV, inhaled nitric oxide) must also be considered. Each of these aspects requires individual assessment, as specific thresholds have not been firmly established.

Current eligibility criteria for ECLS were issued at the PALICC-2 conference in 2023 and modify

the 2015 recommendations. They take into account the strength of recommendation, quality of evidence and expert agreement [5, 6]:

1. Patients with a potentially reversible cause of severe PARDS should be considered for extracorporeal therapy with ECMO when lung-protective strategies result in inadequate gas exchange. Conditional clinical recommendation (CR); very low quality of evidence; 96% agreement.
2. The decision to initiate ECMO should be based on a careful assessment of the disease course and clinical condition by an expert team. Good practice (GP); 94% agreement.
3. Decisions on initiating ECMO should be based on serial rather than single-time-point assessment. Conditional CR; low quality of evidence; 98% agreement.
4. VV ECMO rather than VA ECMO is suggested in patients with PARDS and preserved cardiac function. Conditional CR; low quality of evidence; 94% agreement.
5. Patients with PARDS who fail to stabilise with optimal non-ECMO therapies should be considered for transfer to an ECMO centre. GP; 96% agreement.
6. No recommendation can be made on the use of ECCO₂R in patients with PARDS; further studies are needed to define clinical indications in this group. Research statement (RS); 92% agreement.

Current key eligibility criteria for ECLS are [1, 10]:

- Severe respiratory failure with PaO₂/FiO₂ < 60 mmHg for 3 hours, or PaO₂/FiO₂ < 80 mmHg, or OI > 40 for 6 hours (OI = MAP × FiO₂ × 100/PaO₂).
- No response to conventional ventilation and/or other rescue therapies (e.g. prone positioning, high-frequency ventilation, inhaled nitric oxide).
- Elevated ventilator parameters: mean airway pressure (MAP) > 20–25 cmH₂O.
- Persistent severe respiratory acidosis (pH < 7.1), with the decision on ECMO taken within fewer than 7 days of maximal ventilation.

The EOLIA (ECMO to Rescue Lung Injury in Severe ARDS) criteria may also be applied. Combes *et al.* [11] assessed the impact of early ECMO in adults with the most severe forms of ARDS. Eligible patients met the American-European Consensus Conference ARDS definition, were intubated and ventilated for fewer than 7 days, and despite optimal ventilator settings still met at least one of the predefined severity criteria. These thresholds are now widely used as cut-offs for ECMO in adults with severe ARDS:

- PaO₂/FiO₂ < 50 mmHg for more than 3 hours;
- PaO₂/FiO₂ < 80 mmHg for more than 6 hours;
- pH < 7.25 with PaCO₂ > 60 mmHg.

When evaluating children with severe respiratory failure for VV ECMO, it is important to determine

whether the disease is potentially reversible, which is the case in most children but not in most adults. Irreversible, fatal lung diseases such as alveolar capillary dysplasia or surfactant deficiency are exceptionally rare and occur mainly in neonates. In older children with irreversible conditions such as cystic fibrosis, ECLS may be considered as adjunctive therapy during acute exacerbations or as a bridge to lung transplantation.

In children, severe hypoxia and/or hypercapnia are indications for VV ECMO regardless of the type and dose of inotropes [12, 13]. In coexisting shock, VA ECMO or hybrid VAV ECMO is preferred to provide mechanical circulatory support.

Contraindications to extracorporeal oxygenation are divided into absolute and relative, with reasoned consideration of relative contraindications as situations in which the procedure is unlikely to be beneficial yet carries substantial risk [10, 14].

Absolute contraindications:

- lethal chromosomal aberration;
- irreversible central nervous system (CNS) injury;
- intraventricular haemorrhage > grade III.

Relative contraindications:

- mechanical ventilation with 100% O₂ for more than 14 days;
- irreversible organ damage;
- high probability of poor prognosis;
- neurosurgical procedure within the past week.

ECLS should also be considered carefully in so-called high-risk patients with a potentially poor prognosis, in whom benefit is unlikely:

- large intracranial haemorrhage with mass effect;
- sudden cardiac arrest from hypoxia without adequate cardiopulmonary resuscitation;
- irreversible underlying cardiac or pulmonary pathology not amenable to transplantation;
- pulmonary hypertension and chronic lung disease;
- chronic multi-organ failure;
- vascular anomalies and/or prior vascular interventions for ECMO and/or infection at the cannulation site;
- incurable malignancy;
- allogeneic bone marrow transplant recipients;
- conditions with poorer prognosis in respiratory ECLS: liver or renal failure; pertussis in infants; fungal pneumonia; cytomegalovirus infection; immunodeficiency.

VV ECMO may also be initiated outside these criteria when the patient is unstable and cannot safely complete the PARDS algorithm because conventional strategies (e.g. prone positioning) cannot be performed safely or are unavailable locally, and ECMO is required for safe transfer to an experienced centre (so-called rescue ECMO). Likewise, in patients

who have exceeded standard eligibility criteria and the decision to start ECMO has been delayed, ECMO may still be considered as “rescue” therapy [11, 15].

In an era of continuous improvement of ECLS technology and equipment, complication rates are likely to decrease; further research is therefore needed on the role of VV ECMO in severe respiratory failure in the paediatric population, with definition of triggers, indications and contraindications [9].

PATIENT OPTIMISATION

Before initiating ECMO, advanced ventilator strategies and measures to optimise the patient's overall condition should be exhausted. These include:

1. Exclusion or correction of potentially reversible causes of respiratory failure.
2. Ventilation according to LPS principles with TV 6–8 mL kg⁻¹ of ideal body weight (IBW), or 4–6 mL kg⁻¹ if required to keep P_{plat} below the recommended limits (P_{plat} ≤ 28 cmH₂O, or ≤ 32 cmH₂O with reduced chest-wall compliance, and DP ≤ 15 cmH₂O) [6].
3. PEEP titration according to PaO₂, FiO₂, haemodynamics and respiratory system compliance, with PEEP set at or above the level specified in the low-PEEP/FiO₂ table of the ARDS Network (ARDSNet) [6].
4. Recruitment manoeuvres are not routinely recommended; when used, they should incorporate individualised titration of optimal PEEP for oxygenation while minimising the risk of barotrauma [1].
5. HFOV may be beneficial in children with severe ARDS, although evidence for superiority over conventional mechanical ventilation (CMV) is lacking. Airway pressure release ventilation (APRV) may also be used, but there is no evidence that it reduces mortality or the need for ECLS. ELSO advises clinicians to use the modes they have most experience with in severe paediatric respiratory failure [1].
6. Prone positioning. Data in children show improved gas exchange through better ventilation-perfusion (V/Q) matching, but no convincing effect on clinical outcomes. Despite the absence of definitive paediatric data, strong evidence in adults and physiological rationale support the use of prone positioning before ECMO whenever it can be performed safely [16]. Clinical experience suggests the greatest benefit when atelectasis is predominantly in the dorsal regions of the lung.
7. Inhaled nitric oxide (iNO). Available data on iNO before ECLS are inconsistent [17, 18]. PALICC guidelines suggest a trial of iNO before ECLS,

particularly in patients with pulmonary hypertension or right ventricular dysfunction; in haemodynamically unstable patients, iNO must not delay ECMO [6].

8. Adequate sedation and neuromuscular blocking agents (NMBA). These should be considered early in the management of severe respiratory failure, especially when sedation alone does not allow optimal mechanical ventilation [19].
9. Careful, frequent and gentle airway suctioning to minimise the risk of derecruitment; no recommendation is made for closed versus open suction systems.
10. Other adjunctive therapies such as surfactant or corticosteroids are not supported by sufficient evidence for routine use in children with severe respiratory failure. Some benefit of glucocorticoids may exist in PARDS caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but data are insufficient to recommend their use in other specific patient populations.
11. Optimal fluid management to ensure adequate oxygen delivery and organ function while avoiding overload; continuous renal replacement therapy should be used when required.
12. Cardiovascular optimisation. All patients with PARDS should undergo haemodynamic monitoring to assess how ventilation and the disease itself affect right and left ventricular function, and to evaluate oxygen delivery.
13. Prevention of ventilator-associated pneumonia (VAP) through hand hygiene, oral antiseptic care, endotracheal cuff pressure ≥ 20 cmH₂O, semi-recumbent positioning, ventilator circuit changes only when visibly soiled, removal of circuit condensate away from the patient, and minimisation of ventilation time. Risk factors for VAP include enteral nutrition, proton pump inhibitors or H₂-receptor blockers, reintubation, secretion aspiration, contaminated equipment, prolonged ventilation, and coexisting genetic, neurological or cardiovascular disorders [20].
14. Monitoring of FiO₂, SpO₂ and/or PaO₂, MAP and PEEP to confirm the PARDS diagnosis, assess severity and guide therapy.
15. Before planned transport, a ventilation trial using the transport ventilator should be performed under intensive-care conditions to confirm the safety and efficacy of that ventilator setup during transport [2].

ORGANISATION OF THE ECMO TEAM

Implantation of the ECMO circuit in its basic VV and VA configurations is a standard procedure usually performed in a cardiac surgery operating

theatre, under aseptic conditions, with the equipment typical for cardiopulmonary bypass and with the inherent risk of massive bleeding [2]. It should therefore be performed by a highly specialised team. In a patient with PARDS treated in a paediatric anaesthesiology and intensive care unit at a hospital without a paediatric cardiac surgery department, the procedure may need to be performed on site before transfer to a referral centre, where ECMO will continue. Appropriate on-site conditions must therefore be ensured before so-called ECMO transport, in cooperation with the retrieval team.

Implantation and the subsequent success of ECMO support depend on close teamwork, especially at hospitals without paediatric cardiac surgery where local experience is limited. The team required to initiate ECMO and its responsibilities are listed below:

- Anaesthesiology and intensive care consultant: anaesthesia and intensive care of the patient (ASA IV–V).
- Anaesthesiology and intensive care consultant or general, vascular or cardiac surgeon (operator): cannula placement and connection to the ECMO circuit.
- Operator's assistant: assists during circuit implantation.
- Perfusionist: circuit preparation, check and start-up, monitoring of device parameters.
- Anaesthesia nurse: assists with anaesthesia in the ASA IV–V patient and provides intensive care.
- Operating room nurse: assists during the vascular procedure.
- Radiographer: radiological monitoring.

The operating room must meet all standard requirements for implantation, connection and start-up of ECMO, and the following additional equipment is required [21]:

- Ultrasound with a linear probe of at least 11 MHz and a sector probe of 2–5 MHz (transthoracic echocardiography).
- Mobile C-arm or stationary radiography unit.
- At least 2 units of red blood cell concentrate (RBC) and 1 unit of thawed, ready-to-use fresh frozen plasma (FFP); for patients with body weight below 15 kg, RBC must be stored for less than 5 days.
- Vascular catheters dedicated to ECMO and their introducer sets, suitable for both children and adolescents, provided by the ECMO retrieval team.

For VV ECMO, vessel cannulation can be performed with two venous catheters in a femoral-internal jugular or femoral-femoral configuration, or with a single dual-lumen catheter inserted via the internal jugular vein [22]. The choice depends on the patient's anatomy and vessel diameter. Doppler ultrasound assessment of the vessels before

referral is good practice. Cannulation is performed using the Seldinger technique under ultrasound guidance, or by surgical cut-down [23]. Correct cannula position is confirmed by chest radiography and/or transthoracic or transoesophageal echocardiography (TTE/TEE), depending on availability and operator experience [24].

For VA ECMO, peripheral access options include femoral vein/femoral artery and jugular vein/femoral artery; central access uses the aortic arch and right atrium. Peripheral cannulation can be performed by surgical cut-down of the artery, whereas central access requires thoracotomy [25].

Retrieval team

Implantation and start-up of ECMO at the referring hospital, before transfer to the referral centre (a paediatric anaesthesiology and intensive care unit at a hospital with paediatric cardiac surgery), require the equipment and personnel described above. The greatest challenge is that the retrieval team and the referring hospital must cooperate without having worked together before, in a setting unfamiliar to the retrieval team, during a procedure the local team has never witnessed, and in a critically ill patient. To make this as safe as possible, the most experienced clinician on the retrieval team takes responsibility for the equipment and supplies, the ECMO procedure and intensive care from ECMO initiation until completion of transport [26]. Following cannulation and stabilisation, the patient is transferred on ECMO to the referral centre.

The ambulance used during ECMO transport must allow standard intensive care of the critically ill patient, particularly in the first hours after implantation when homeostasis has yet to be reached. Access to the patient from at least two sides (head and side) and access to drugs, supplies, the control console and monitors must be possible throughout transport without unfastening seat belts during vehicle movement [27]. The next requirement is reliable powering of equipment that needs O₂ and 230 V AC. Battery operation is reserved for "boarding" (moving the stretcher from the operating theatre to the ambulance and from the ambulance to the paediatric intensive care unit) and for emergencies. The patient on extracorporeal therapy is highly susceptible to iatrogenic hypothermia and requires adequate protection [28, 29]; cannulae often lack factory-fitted retention devices. Despite VV ECMO support, the patient often requires aggressive ventilation with careful adjustment of PEEP, peak inspiratory pressure (Pi), respiratory rate (RR) and inspiratory-to-expiratory (I/E) ratio. The decision to initiate ECLS should take the indications and contraindications into account; external factors such as weather

or distance from the referring hospital should not preclude ECMO transport provided maximum safety can be maintained. The vehicle must meet the following requirements:

- onboard generator/auxiliary power unit (APU) or 12 V DC/230 V AC inverter of at least 2,000 W;
- auxiliary heating system, independent of the engine and external power;
- oxygen supply: at least four 8-litre cylinders and three 2-litre portable cylinders; this is the basic provision and should be increased depending on the patient's condition, ventilator settings and expected transport duration;
- backup ventilator;
- medical bag compliant with the Polish State Fire Service medical rescue kit (PSP R1) standard;
- communication devices for all team members (GSM and PMR [private mobile radio]);
- spare infusion pumps;
- fuel reserve and a mains cable to permit a forced stop.

In favourable weather and over long distances between the referring hospital and the referral centre, support by medical air transport (HEMS) is an option [30]. Air transport must be performed by an aircraft meeting the same equipment requirements as a specialist ambulance.

SELECTED ASPECTS OF TREATMENT IN PATIENTS ON VV ECMO

Management of paediatric patients with respiratory failure on VV ECMO is complex and requires experience. Such patients should be managed in centres experienced in ECMO. The team caring for a child with PARDS on VV ECMO faces multiple challenges [1].

Anticoagulation

During ECMO, contact of the patient's blood with the non-endothelial surfaces of cannulae and the oxygenator activates coagulation, with a risk of circuit thrombosis and/or thromboembolism in the patient. Safe and effective ECMO therefore requires systemic anticoagulation [31]. Connection to the circuit causes haemodilution and dilutional coagulopathy, platelet activation and shear-stress damage, haemolysis, damage to von Willebrand factor multimers, fibrinolysis activation and initiation of an inflammatory response. The patient's own coagulation status also influences the picture: clotting factor and platelet levels, and any prior activation of coagulation. The ECMO patient is thus simultaneously at high risk of bleeding and of thromboembolic complications [32]. Anticoagulation and treatment of coagulopathy must be managed in parallel. The aim is to prevent clots in the ECMO

TABLE 2. Summary of available coagulation tests

Test	Strengths	Limitations
ACT	Whole-blood test; assesses the end-effect of the coagulation cascade Inexpensive Available as a point-of-care test	Influenced by platelet count and function, fibrinogen, clotting factors, D-dimers and other factors affecting haemostasis: hypothermia, haemodilution, anaemia No standardisation of devices and tubes Poor correlation between result and heparin concentration or anti-Xa activity
aPTT	Plasma test; "gold standard" for monitoring UFH outside ECMO Widely available	Variable response: the same UFH dose produces less prolongation of aPTT in young children than in older children and adults Also affected by clotting-factor deficiency, hyperbilirubinaemia, hyperlipidaemia and antiphospholipid antibodies No standardisation of reagents
Anti-Xa	Assesses the AT III-dependent inhibition of factor Xa by heparin Independent of clotting factors and platelets Better correlation with UFH dose and concentration	Limited availability Falsely low at plasma-free haemoglobin > 50 mg dL ⁻¹ , triglycerides > 500 mg dL ⁻¹ or bilirubin > 6 mg dL ⁻¹
Global haemostasis tests (TEG, ROTEM)	Whole-blood tests; point-of-care; provide information on clot strength and fibrinolysis	Limited availability and experience High cost

ROTEM – rotational thromboelastometry, TEG – thromboelastography

TABLE 3. Frequency of coagulation testing

Test	Frequency
ACT	Every 1–2 hours for the first 6 hours, then every 6 hours
aPTT	Every 6–12 hours
Anti-Xa	Every 6–12 hours
PLT	Every 6–12 hours
INR	Every 12–24 hours
Fibrinogen	Every 12–24 hours
WBC	Every 12–24 hours
AT III	Every 24 hours
Plasma-free haemoglobin	Every 24 hours
TEG/ROTEM	Every 24 hours; additionally during bleeding or thrombosis

ACT – activated clotting time, anti-Xa – anti-factor Xa, AT III – antithrombin III, INR – international normalized ratio, aPPT – activated partial thromboplastin time, PLT – platelet count, ROTEM – rotational thromboelastometry, TEG – thromboelastography, WBC – white blood cell

circuit while maintaining adequate coagulation in the patient.

The mainstay anticoagulant is unfractionated heparin (UFH). Advantages are extensive experience, short half-life, availability of an antidote. Disadvantages include variable pharmacokinetics with age (half-life in children 35–75 minutes), dependence on antithrombin III, and hence unpredictable patient response, possible heparin resistance, lack of a reliable monitoring method, and the risk of heparin-induced thrombocytopenia [33].

The standard bolus dose at circuit start-up is 50–100 IU kg⁻¹.

In prior bleeding, surgery or cardiopulmonary bypass, a lower dose should be considered. After

the first heparin dose, activated clotting time (ACT) should be monitored every 30 minutes [34].

Heparin infusion is started when ACT falls below 180–200 s. Doses are usually higher than in adults: 28 IU kg⁻¹ h⁻¹ in infants and 20 IU kg⁻¹ h⁻¹ in children over 1 year old [34].

Monitoring of heparin anticoagulation should combine activated partial thromboplastin time (aPTT), ACT, anti-factor Xa (anti-Xa) activity and so-called global coagulation tests [1, 34, 35].

Limitations and strengths of available coagulation tests

Summary of available coagulation tests is shown in Table 2. The suggested test frequency [1, 31] is shown in Table 3.

Tests (aPTT, ACT or anti-Xa) are also performed 4 hours after FFP or antithrombin III (AT III) administration. Recommended targets [31]:

- anti-Xa activity 0.35–0.7 IU mL⁻¹;
- aPTT 1.5–2.5 times baseline;
- ACT, most often recommended at 180–220 seconds, which may vary by device.

Where significant discrepancies between results are found, potential causes should be analysed in detail.

In selected situations such as heparin-induced thrombocytopenia (HIT), heparin resistance, or circuit thrombosis despite adequate anticoagulation, bivalirudin may be an alternative [36]. Current evidence is insufficient to recommend bivalirudin as first-line therapy.

Bivalirudin is a direct thrombin inhibitor that binds both free and clot-bound thrombin. It is meta-

bolised mainly by proteolytic enzymes, with 20% renal excretion. Paediatric half-life is 15–42 minutes but is prolonged in renal failure. Advantages include a predictable effect and stable anticoagulation. Disadvantages include limited experience, high cost, no specific antidote, and no specific monitoring assay. Treatment is generally monitored by aPTT, target 60–90 seconds.

Strategy for blood and blood-product transfusion in children on VV ECMO

According to ELSO guidelines [34] and the Paediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative (PEACE) Consensus Conference [35], transfusion of blood and blood products in ECMO patients should be restricted.

Red blood cell concentrate: No clear recommendation has been issued on the optimal haemoglobin level in a child on ECMO. The 2021 ELSO guidelines [31] suggested Hb > 7–9 g dL⁻¹, except in neonates, in children with cyanotic congenital heart disease and in patients with persistent hypoxaemia despite increased ECMO blood flow. This recommendation was not upheld by the PEACE Consensus Conference; in the absence of bleeding, the transfusion decision depends on the clinical picture and on overall oxygen consumption and delivery rather than haemoglobin alone.

Plasma: There is no benefit from prophylactic transfusion of plasma or clotting-factor concentrate when international normalized ratio (INR) < 1.5.

Platelet concentrate: There is no benefit from prophylactic platelet transfusion when platelet count is > 100 000 μL^{-1} .

Fibrinogen: In patients with fibrinogen < 1 g L⁻¹, prophylactic cryoprecipitate and/or fibrinogen concentrate may be considered to prevent bleeding.

Antithrombin III: There are no data on routine AT III administration in ECMO patients. When a therapeutic effect cannot be achieved despite escalating heparin doses, AT III may be considered. Target activity: AT III > 50–80%. After administration, coagulation tests and clinical assessment for bleeding or thrombosis should be repeated.

Bleeding prophylaxis: Topical haemostatic agents are recommended for bleeding prophylaxis.

Management for procedures with low bleeding risk on VV ECMO

These are procedures in which bleeding is easy to recognise and control:

1. Consider reducing or pausing anticoagulation, depending on the procedure, site, and bleeding and thrombosis risk.
2. Use topical haemostatic agents.
3. Routine antifibrinolytics are not justified.

Management for procedures with high bleeding risk on VV ECMO

1. Consider antifibrinolytics before the procedure and for at least 24 hours afterwards.
2. Maintain platelets > 100 000 μL^{-1} and fibrinogen > 150 mg dL⁻¹.
3. Use topical haemostatic agents.
4. Consider reducing or pausing anticoagulation, depending on the procedure type and site, the possibility of surgical haemostasis, the patient's condition and the state of the circuit.
5. Recombinant factor VII (rFVIIa) is not recommended because of the high thrombotic risk, except for life-threatening bleeding refractory to transfusion.

Management of haemorrhage on VV ECMO

1. Maintain:
 - PLT > 100 000 μL^{-1} , or higher in the presence of platelet dysfunction;
 - INR < 1.5;
 - Fibrinogen > 1.5 g L⁻¹.
2. In active haemorrhage, consider reducing or pausing anticoagulation.
3. In bleeding refractory to transfusion, antifibrinolytics and reduced/paused anticoagulation, consider prothrombin complex concentrate.
4. In massive haemorrhage, activate a massive transfusion protocol with balanced resuscitation using blood and blood products.
5. In massive haemorrhage with signs of consumptive coagulopathy, evaluate all potential causes including the state of the circuit, patient thrombosis or the development of disseminated intravascular coagulation.

Nutritional support

Critically ill children on ECMO develop metabolic disturbances driven by a generalised inflammatory response and hypermetabolism, with markedly increased energy requirements, deficits and losses of protein and micronutrients, renal dysfunction and electrolyte disturbances. ECMO patients have an increased protein requirement, as protein catabolism is more pronounced than in any other critically ill group. Many are already malnourished before ECMO begins. In paediatric ECMO patients, malnutrition is an independent risk factor for in-hospital mortality, morbidity and prolonged ECMO duration [37].

1. Nutritional status should be assessed at the start of ECMO and monitored throughout: body weight, height-for-weight, anthropometric measurements and albumin levels.
2. Basal energy requirement should be calculated using the Schofield equation (Table 4) [38]. Total requirement depends on the underlying disease

TABLE 4. Schofield equation

Age (years)	Girls	Boys
< 3	$58.317 \times BW - 31.1$	$59.512 \times BW - 30.4$
3–10	$20.315 \times BW + 485.9$	$22.706 \times BW + 504.3$
10–18	$13.384 \times BW + 692.6$	$17.686 \times BW + 658.2$

BW – body weight (kg).

and treatment (sedation, mechanical ventilation) and may exceed the basal requirement several-fold (for example, by 300% in sepsis) [39].

3. Minimum protein intake should be $1.5 \text{ g kg}^{-1} \text{ d}^{-1}$.
4. Enteral nutrition should be the primary route; in addition to delivering energy and nutrients, it supports gut function (gut-associated lymphoid tissue [GALT] and the intestinal microbiome) and reduces the risk of bacterial translocation. Critical illness is, however, often accompanied by feed intolerance: gastroparesis, gastro-oesophageal reflux, impaired bowel motility, intestinal ischaemia, paralytic ileus and dysbiosis, leading to vomiting, gastric residuals, diarrhoea or constipation that prevents initiation or continuation of enteral nutrition. Strategies to support gastrointestinal function include prokinetics, minimising sedation, elevating the upper body by $30\text{--}45^\circ$, post-pyloric feeding tubes, formula changes, laxatives, and switching from continuous infusion to small-bolus delivery.
5. Implementation of nutritional support is summarised in Figure 1.

Sedation

The aim of sedation is to ensure patient comfort and safe operation of the VV ECMO circuit. General principles do not differ from other paediatric ICU settings. Sedation depth should be monitored with the COMFORT-B scale at least twice daily [39]. Analgosedation is provided as an opioid infusion (morphine, fentanyl, sufentanil), with benzodiazepines and/or dexmedetomidine or clonidine. Non-

opioid analgesics (paracetamol and metamizole) should be added. Ketamine infusion is also recommended when deeper sedation is required. Because of the risk of propofol infusion syndrome, propofol infusions of more than 48 hours or at doses above $4 \text{ mg kg}^{-1} \text{ h}^{-1}$ are not recommended [39].

Maintaining the patient's own respiratory drive appears beneficial, as it supports pulmonary rehabilitation. Excessive respiratory effort, however, may increase the transpulmonary pressure gradient and lead to patient self-inflicted lung injury (P-SILI) [40].

In specific situations such as hypermetabolic states with high oxygen consumption, neuromuscular blocking agents may be useful, with monitoring of the degree of blockade. Instrument-based methods of sedation depth (e.g. BIS, SedLine) are available but have no firm paediatric recommendations.

Analgosedation is often associated with impaired gastrointestinal function, disuse muscle atrophy, tachyphylaxis and dose escalation, all of which directly increase the risk of delirium and withdrawal during weaning. These considerations have led to the concept of extubating patients and managing them on ECMO without mechanical ventilation, thus avoiding deep sedation ("awake ECMO"). This is particularly relevant for patients expected to require prolonged therapy, such as those awaiting lung transplantation. ELSO Registry data for 2018–2022 show that 4.8% of paediatric ECMO patients were managed while breathing spontaneously. The non-intubated group had shorter ICU stays and faster mobilisation and rehabilitation. However, mortality was higher in this group, and the authors note that an association between extubation and mortality cannot be excluded. At this stage, extubation of patients on ECMO is recommended only in centres with extensive experience [41].

Fluid management

Fluid overload of 10% during ECMO may be associated with longer therapy and higher mortality, and prevention or correction of overload is an important factor in improving pulmonary function and reducing ECMO duration [42–44]. Fluid overload is calculated as the ratio of daily cumulative fluid balance to admission body weight:

$$\% \text{ fluid overload} = (\text{fluid balance} / \text{admission body weight}) \times 100$$

Principles of fluid management in ECMO patients [45]:

1. Fluid balance should be reviewed at least every 12 hours.
2. Aim for a negative fluid balance.
3. Restrict fluids to those essential, and concentrate solutions.




FIGURE 1. Nutritional support algorithm in children on ECMO

4. Maintain urine output sufficient to achieve the target balance.

5. Consider albumin to maintain serum albumin $> 2.5 \text{ g dL}^{-1}$.

6. If overload develops despite fluid restriction and diuretics, start renal replacement therapy (RRT) [46].

RRT may be delivered as continuous renal replacement therapy, or less commonly as peritoneal dialysis or intermittent haemodialysis. Continuous techniques (haemofiltration or continuous veno-venous haemodiafiltration [CVVHDF]) are used most often because they allow stable, controlled fluid removal with haemodynamic stability. RRT can be connected to the ECMO circuit in three ways: a separate venous access, in-line addition of a haemofilter to the ECMO circuit, or integration of a CVVHDF device into the circuit.

According to ELSO recommendations, the CVVHDF device is connected to the venous (return) line [47]:

- blood is drawn after the pump, either before or after the oxygenator;
- blood is returned before the oxygenator.

Early initiation of RRT may favourably affect duration of ECMO support and survival [45, 47].

Ventilation

Extracorporeal oxygenation minimises the risks of barotrauma, volutrauma, atelectotrauma and biotrauma associated with mechanical ventilation.

Recommendations [1, 48]:

1. Suggested ventilator settings: $\text{FiO}_2 < 50\%$, PIP $< 25 \text{ cmH}_2\text{O}$, PEEP 5–15 cmH_2O , respiratory rate 10–20 min^{-1} , inspiratory time 0.8–1 second.
2. Ventilation should take account of the pathophysiology of the underlying disease; for example, inspiratory time should be shorter in status asthmaticus.
3. Pneumothorax and any pleural fluid or blood should be drained.
4. Airway clearance should be performed meticulously, including bronchoscopic suction where indicated.
5. Recruitment manoeuvres are not recommended.

Other aspects of care for the ECMO patient [1]

1. Rehabilitation: physiotherapy should be started as early as possible after haemodynamic stabilisation and once ventilator parameters (especially PEEP) are stable, following the principle of early mobilisation. Identify patients suitable for passive exercises and those who can engage in active rehabilitation.
2. Eye care. Patients unable to close their eyes are at risk of keratopathy with ulceration and infection. The eyes should be examined at least every

TABLE 5. Incidence of selected complications per 1,000 hours of paediatric VV ECMO

Complication	Incidence
Haemolysis	1.039
Renal replacement therapy	0.875
Circuit change	0.636
Circuit thrombosis	0.545
Cannula malfunction	0.534
Cannulation-site bleeding	0.343
Pneumothorax requiring drainage	0.261
Surgical-site bleeding	0.227
Central nervous system haemorrhage	0.179
Air in the circuit	0.152
Seizures	0.134
Gastrointestinal bleeding	0.123
Stroke	0.097

12 hours. Lubricating drops and protective covers to prevent drying are recommended.

3. Pressure-ulcer prevention.

4. Oral hygiene.

Infection control: there is no rationale for routine prophylactic antibiotic therapy.

COMPLICATIONS OF ECMO

VV ECMO is a highly specialised therapy used predominantly in patients with severe respiratory failure. Survival in this group exceeds that of VA ECMO, but the therapy still carries substantial risks of specific mechanical and haematological complications. Complications can be grouped as haematological, neurological, infectious and equipment-related (Table 5). Survival at 24 hours after decannulation and to hospital discharge is 74.5% and 63.8%, respectively [49]. The median duration of therapy is 188 hours [49].

Bleeding

Incidence

Bleeding is a common complication of paediatric VV ECMO; reviews indicate significant bleeding in up to about 40–50% of children. The most frequent sites are the surgical wound, cannulation site, CNS, lungs and gastrointestinal tract [50, 51].

Monitoring

- Routine measurements: complete blood count (platelets), PT/INR, aPTT, ACT, fibrinogen, D-dimers, anti-Xa [35].
- During bleeding, fibrinogen should be monitored and maintained at $\geq 150 \text{ mg dL}^{-1}$ ($\geq 1.5 \text{ g L}^{-1}$) [52].
- Inspect cannulation sites, drains, surgical sites and assess for internal bleeding (lungs, gastrointestinal tract).

Management

- In active bleeding: correct haemostasis (replace fibrinogen, platelets and clotting factors) and modify the anticoagulation strategy (lower dose, change of agent).
- In difficult-to-control bleeding: consider replacing components of the VV ECMO circuit, or reducing flow if feasible. Detailed management is discussed by Rintoul *et al.* [53].
- The transfusion strategy (red cells, platelets, cryoprecipitate) should take into account the risk of thrombosis.
- Iatrogenic blood loss from laboratory sampling should be minimised.

Thrombosis/clotting

Incidence

Thrombosis within the VV ECMO circuit or in the patient is reported in approximately 20–30% of cases [35, 50].

Monitoring

- Routine assessment of coagulation: aPTT/ACT/anti-Xa, fibrinogen, platelets, AT III, prothrombin time.
- Circuit monitoring: flow, pre- and post-oxygenator pressures, inspection of lines, pump and filters for thrombus.

Management

- If a thrombus is detected in the circuit: replace components (oxygenator, pump or lines) promptly; review flow settings and cannula position.
- Adjust anticoagulation: if clots occur on a “standard” dose, consider increasing anticoagulation, changing the agent or modifying the haemostasis protocol [54].

Haemolysis

Incidence

Haemolysis is among the more common mechanical complications of paediatric VV ECMO and may lead to renal injury and increased risk of coagulation-related complications. Clinically significant haemolysis is defined as plasma-free haemoglobin (pfHb) above 0.5 g L^{-1} or lactate dehydrogenase more than three times the upper limit of normal. Up to 43.5% of patients develop severe haemolysis (pfHb $\geq 1.0 \text{ g L}^{-1}$). Dalton *et al.* [51] found that higher haemoglobin and more frequent red cell transfusions were associated with increased haemolysis, whereas well-managed anticoagulation was protective. Monitoring of haemoglobin, pfHb and signs of haemoglobinuria is central; in rising haemolysis, mechanical causes such as thrombus in the pump or oxygenator, abnormal flow or suboptimal cannula position must be excluded. Correction

of pump and flow settings and, when necessary, replacement of circuit components (oxygenator/pump) are the mainstays of management [55].

Neurological complications

Incidence

Seizures and other neurological complications occur in around 15% of cases; the majority are subclinical. They are more frequent after extracorporeal cardiopulmonary resuscitation (ECPR) and in children supported on VA ECMO [56].

Monitoring

- Regular neurological examination: level of consciousness, reflexes, focal signs; imaging (CT/MRI) when intracranial haemorrhage or thrombosis is suspected.
- Continuous EEG monitoring is recommended.

Management

- On detection of intracranial haemorrhage or stroke: collaboration with neurology/neurosurgery; consideration of changing or reducing anticoagulation; clinical decisions on continuation of VV ECMO in light of neurological prognosis.
- Prevention: avoid aggressive mechanical ventilation, control intracranial pressure, maintain adequate anticoagulation.

Infections

Incidence

VV ECMO-related infections (cannulation-site infection, bacteraemia) occur in approximately 10–20% of patients. Risk rises with duration of therapy. Infection is associated with an approximately two-fold increase in mortality. *Candida* spp. are notable pathogens [9].

Monitoring

- Daily inspection of cannulation sites (erythema, exudate).
- Routine laboratory tests: C-reactive protein/procalcitonin, blood and urine cultures when infection is suspected.
- Track duration of VV ECMO; longer support is a risk factor.

Management

- Routine antibiotic prophylaxis during VV ECMO remains controversial; current ELSO guidance does not recommend it routinely [1]. If infection is suspected, promptly initiate empirical antibiotic therapy, obtain microbiological samples, and consider cannula relocation or replacement if the insertion site is suspected to be the source of infection.

- Strict aseptic technique during all VV ECMO handling, minimisation of unnecessary circuit changes, and prompt termination of therapy when possible.
- Regular technical checks in cooperation with the perfusionist, scheduled circuit-change protocols based on time in service, and planned, controlled component replacement to avoid sudden failure at a critical moment.

Cannulae and recirculation

Incidence and significance

A specific technical issue in VV ECMO is recirculation: direct return of oxygenated blood into the drainage limb. Recirculation depends on the relative position of drainage and return cannulae, the flow rate and the patient's blood volume. High recirculation (> 25–30%) reduces effective oxygen delivery and manifests clinically as low systemic saturation despite normal VV ECMO parameters. Small vessel diameter is a further technical limitation; in children weighing less than 15 kg, femoral cannulation is discouraged. The risk of cannula kinking with small sizes should be considered, as should the lesser stability of such cannulae, given the short insertion path and poorly developed subcutaneous tissue [1].

Monitoring

- Assessment of oxygenation efficacy (saturation, PaO₂), measurement of pre-oxygenator blood saturation, ultrasonographic confirmation of cannula position.

Management

- Secure cannula fixation to prevent displacement. If recirculation is suspected, reposition the cannula, change configuration (e.g. to a dual-lumen cannula or another arrangement) and ensure adequate flow [57].

Equipment failure

Incidence

Failure of the oxygenator, pump or lines can lead to haemolysis and impaired gas exchange and, consequently, worse outcomes. Paediatric data indicate that circuit component replacement is required in approximately 10–15% of therapies [58].

Monitoring

- Pre- and post-oxygenator pressures (a rising gradient may indicate a problem); a fall in gas-exchange efficiency (rising PaCO₂, falling PaO₂); rising haemolysis markers (pfHb); pump flow and pressure; visual inspection of the lines.

Management

- When deterioration is detected, a prompt decision should be made to replace the affected component (oxygenator/pump/circuit).

WEANING AND DECANNULATION FROM VV ECMO

Timely termination of extracorporeal mechanical support is as important as its initiation. VV ECMO should be discontinued when progressive recovery and return of native lung function can be demonstrated, the child tolerates gradual reduction of VV ECMO support, and reduction does not cause clinically meaningful deterioration in gas exchange [1].

ECMO is an aggressive therapy with potential for serious complications. Duration should be as short as possible, and every ECMO patient should be assessed daily for response to therapy and readiness for weaning and continuation of care with less invasive techniques (e.g. mechanical ventilation) [59].

When optimal recovery of pulmonary, cardiac and other organ function has been achieved, a "weaning trial" can be performed to obtain as much information as possible on the likelihood of successful VV ECMO discontinuation. The trial is a diagnostic, not therapeutic, intervention. It allows determination of the patient's readiness to continue care without VV ECMO.

Definition

Successful termination of VV ECMO is defined as 48-hour survival of the child after extracorporeal mechanical gas-exchange support is stopped, without need to restart extracorporeal therapy [1].

Criteria for termination of VV ECMO therapy

Weaning from veno-venous support is one of the most difficult aspects of ECMO care. There are three categories of decision to terminate extracorporeal support:

1. Clinical improvement, with reasonable confidence that ECMO can be successfully terminated.
2. Low likelihood of successful termination, but ECMO cannot be continued because of complications or high risk thereof.
3. Termination because of a fatal, incurable disease or severe complications (compassionate withdrawal).

In the first case, before terminating ECMO, a decision should be made whether the patient will be re-eligible for ECMO in the event of failure to wean, and under what circumstances.

In the third case, ECMO is withdrawn as part of palliative care after discussion with the family, in the last phase of life, when withdrawal allows natural death from the underlying disease.

TABLE 6. Factors considered in the decision to terminate VV ECMO

1. Clinical improvement in the condition that led to VV ECMO
2. Moderate mechanical respiratory support, with satisfactory lung compliance and gas exchange ($P_{\text{plat}} < 30 \text{ cmH}_2\text{O}$ [ideally $25 \text{ cmH}_2\text{O}$], PEEP $8\text{--}12 \text{ cmH}_2\text{O}$, TV $6\text{--}8 \text{ mL kg}^{-1}$ at $\text{FiO}_2 < 0.5\text{--}0.6$, $\text{SaO}_2 > 90\%$, $\text{pH} > 7.3$, PaCO_2 normal or mildly raised)
3. Optimally inflated lungs on chest radiography (no clinically significant pathology such as pleural effusion, pneumothorax, atelectasis)
4. Airway clearance performed
5. Moderate pharmacological circulatory support
6. Echocardiographic ejection fraction $> 25\%$ (depending on underlying pathology) on minimal pharmacological support
7. No fluid overload
8. Adequate sedation depth or no sedation
9. Cardiac surgical team available for decannulation

PEEP – positive end-expiratory pressure, P_{plat} – plateau pressure, TV – tidal volume.

In the second case, short- and long-term outcomes are harder to predict. Switching to less invasive treatment may worsen organ function despite intensive mechanical ventilation and pharmacological circulatory support, while continued ECMO carries an excessive risk of mortality or major morbidity. Before disconnection, a decision should be made on whether, and under what circumstances, the patient will be eligible for re-cannulation onto ECMO.

Table 6 lists the factors to consider before deciding to terminate ECMO [1].

There are no fixed time limits or a single universal weaning algorithm. Each patient has an individual algorithm dictated by the clinical context; this should be recognised and the weaning trial tailored accordingly to maximise the chance of successful liberation.

Weaning trial

ELSO Registry data and case series indicate growing use of VV ECMO in children with respiratory disease [48]. There is also some case-series and registry evidence that survival may be better with VV than VA ECMO. VA ECMO is sometimes chosen at the outset in the most severe PARDS until improvement allows a switch to veno-venous support.

De-escalation differs between VA and VV ECMO.

Weaning from VV ECMO consists of a sweep-gas off trial, the ultimate aim of which is to assess pulmonary function while the ECMO circuit is not contributing to gas exchange. The sweep gas is therefore stopped while blood flow through the ECMO circuit is maintained. During the trial, the patient is on full lung-protective mechanical ventilation, with monitoring of gas exchange, respiratory effort and haemodynamics [60].

The sweep-off trial begins with stepwise reduction of sweep-gas FiO_2 to 0.21 over 20–30 minutes. The 21% oxygen sweep mixture is then maintained for a further 20 minutes (until blood colour in the circuit equalises) while the child is observed for

changes in SpO_2 , respiratory rate, heart rate, blood pressure or rising agitation. After another 20 minutes, the sweep-gas flow is turned off. Gas exchange will then occur only through the lungs. Observation usually lasts 2–6 hours. Adrenaline and inhaled nitric oxide should be on hand in case of pulmonary vasoconstriction and a rise in pulmonary arterial pressure. As sweep-gas flow and FiO_2 are reduced, an arterial blood gas should be obtained every hour, sampled within 30 minutes of each change, to assess oxygenation and ventilation [61]. Sudden cessation of sweep flow lowers a relatively high venous saturation and raises PaCO_2 ; this can substantially disturb V/Q matching, abruptly lower saturation, raise pulmonary vascular resistance and cause the weaning trial to fail. Sequential reduction of sweep-gas FiO_2 before complete cessation is therefore both rational and physiologically grounded.

The child's own lungs should be able to support 50–80% of total gas exchange. In severe lung disease, weaning from ECLS may begin when the native lungs reach 80% of oxygen delivery and respiratory mechanics show substantial improvement [62]. One method of assessing lung recovery is the oxygen challenge test (OCT). ECMO parameters are held constant while FiO_2 is increased to 1.0; the resulting increase in PaO_2 is then assessed. Higher absolute PaO_2 or a larger ΔPaO_2 suggests adequate recovery and the possibility of weaning. Evidence is currently insufficient to define threshold PaO_2 or ΔPaO_2 values for initiating weaning [62].

Available evidence does not support superiority of any specific ventilator mode during VV ECMO weaning [62]. Ventilator settings should, however, be modified to accept PaO_2 values of 60–80 mmHg and PaCO_2 of 40–60 mmHg, allowing lower airway pressures and lower FiO_2 [1].

If ventilatory or haemodynamic problems develop at any point, the weaning trial should be aborted immediately and full ECMO support restored. $\text{SpO}_2 < 88\%$ indicates failed weaning.

If the patient is judged not yet ready for liberation, or the team is not available to decannulate, the circuit FiO_2 should be returned to 100% and sweep gas to the previous setting; mechanical ventilation may be continued or reduced pending decannulation.

Decannulation

Decannulation should ideally be performed in the morning to allow full management of any deterioration. Cannula removal is usually performed by the cardiac surgical team in the paediatric intensive care unit. A plan for managing deterioration after disconnection should be agreed in advance.

Anticoagulation is maintained up to the point of decannulation. In patients with a percutaneous catheter, heparin is stopped one hour before catheter removal. Thirty minutes before cannula removal, a prophylactic dose of an antibiotic such as cefazolin (30 mg kg^{-1}) is given.

Complications after ECMO termination

Complications may occur after successful disconnection even in patients who tolerate the first few hours well. The most commonly reported include bleeding from cannulation sites, limb ischaemia, ischaemia of organs such as the kidneys, liver and nervous system, neurological complications and infections [62].

Risk factors for death after successful ECMO termination include prolonged ECMO support with complications, irreversible organ injury, low pH with high lactate levels, and advanced organ failure [62].

SUMMARY

Extracorporeal cardiopulmonary support should be considered in children with severe respiratory failure when conventional methods fail to provide adequate gas exchange, when they require potentially harmful ventilator settings, or when severe barotrauma occurs. VV ECMO is currently recommended as a treatment option for PARDS, particularly after optimisation of conventional management, including LPS, prone positioning and neuromuscular blockade. VV ECMO may also be used as perioperative support to enable selected procedures such as airway surgery. Because of the small number of methodologically robust studies, current ELSO and PALICC-2 recommendations are general in nature and emphasise the need for further, well-designed studies in this area. The present document synthesises current recommendations with the aim of improving outcomes in paediatric patients with PARDS in Poland.

The patient referral form for ECMO is provided in Appendix 1.

ACKNOWLEDGEMENTS

1. Assistance with the article: None.
2. Financial support and sponsorship: None.
3. Conflicts of interest: None.
4. Presentation: None.

REFERENCES

1. MacLaren G, Brodie D, Lorusso R, Peek G, Thiagarajan R, Vercaemst L, (eds.). Extracorporeal Life Support: The ELSO Red Book. 6th ed. Ann Arbor (MI): Extracorporeal Life Support Organization; 2022.
2. Lango R, Szkulmowski Z, Maciejewski D, Sosnowski A, Kusza K. Revised protocol of extracorporeal membrane oxygenation (ECMO) therapy in severe ARDS. Recommendations of the veno-venous ECMO Expert Panel appointed in February 2016 by the national consultant on anesthesiology and intensive care. *Anestezjol Intens Ter* 2017; 49: 88-99.
3. Bartlett R, Arachichillage DJ, Chitlur M, Rocky Hui SK, Neunert C, Doyle A, et al. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation. *Semin Thromb Hemost* 2024; 50: 81-90. DOI: 10.1055/s-0043-1761488.
4. Lin JC. Extracorporeal membrane oxygenation for severe pediatric respiratory failure. *Respir Care* 2017; 62: 732-750. DOI: 10.4187/respcare.05338.
5. Pediatric Acute Lung Injury Conference Group. Pediatric acute respiratory distress syndrome. *Pediatr Crit Care Med* 2015; 16: 428-439. DOI: 10.1097/PCC.0000000000000350.
6. Emeriaud G, López-Fernández YM, Iyer NP, Bembea MM, Agulnik A, Barbaro RP, et al; Second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) Group. Executive summary of the second international guidelines for the diagnosis and management of pediatric acute respiratory distress syndrome (PALICC-2). *Pediatr Crit Care Med* 2023; 24: 143-168. DOI: 10.1097/PCC.00000000000003147.
7. Silvestre C, Vyas H. Pediatric acute respiratory distress syndrome (PARDS). *Pediatr Child Health* 2021; 31: 229-232. DOI: 10.1016/j.paed.2021.03.001.
8. Zhang Y, Zhou Y, Shi J, Shan Y, Sun T, Wang C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome in children with leukemia/lymphoma: a retrospective case series. *Front Pediatr* 2022; 10: 955317. DOI: 10.3389/fped.2022.955317.
9. Erickson S. Extracorporeal membrane oxygenation in paediatric acute respiratory distress syndrome: overrated or underutilized? *Ann Transl Med* 2019; 7: 512. DOI: 10.21037/atm.2019.09.27.
10. MacLaren G, Conrad S, Peek G. Indications for pediatric respiratory extracorporeal life support. Extracorporeal Life Support Organization (ELSO). Updated: March 2015. Available at: <https://www.heartuniversity.org/wp-content/uploads/ELSO-2014-Guidelines-Indications-for-Pediatric-Respiratory-Extracorporeal-Life-Support.pdf>.
11. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 2018; 378: 1965-1975. DOI: 10.1056/NEJMoa1800385.
12. MacLaren G, Conrad S, Dalton H. Extracorporeal life support. In: Roger's Textbook of Pediatric Intensive Care. Shaffner H, Nichols D (eds.). 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.
13. Roberts N, Westrope C, Pooboni SK, Mulla H, Peek GJ, Sosnowski AW, et al. Venovenous extracorporeal membrane oxygenation for respiratory failure in inotrope-dependent neonates. *ASAIO J* 2003; 49: 568-571. DOI: 10.1097/01.mat.0000084102.22059.91.
14. Zabrocki LA, Brogan TV, Statler KD, Poss WB, Rollins MD, Bratton SL. Extracorporeal membrane oxygenation for pediatric respiratory failure: survival and predictors of mortality. *Crit Care Med* 2011; 39: 364-370. DOI: 10.1097/CCM.0b013e3181fb7b35.
15. Tonna JE, Abrams D, Brodie D, Greenwood JC, Mateo-Sidron JAR, Usman A, et al. Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the Extracorporeal Life Support Organization (ELSO). *ASAIO J* 2021; 67: 601-610. DOI: 10.1097/MAT.0000000000001432.
16. Gattinoni L, Taccone P, Carlesso E, Marini JJ. Prone positioning in acute respiratory distress syndrome: rationale, indications, and limits. *Am J Respir Crit Care Med* 2013; 188: 1286-1293. DOI: 10.1164/rccm.201308-1532CI.
17. Bronicki RA, Fortenberry J, Schreiber M, Checchia PA, Anas NG. Multicenter randomized controlled trial of inhaled nitric oxide for

- pediatric acute respiratory distress syndrome. *J Pediatr* 2015; 166: 365-369. DOI: 10.1016/j.jpeds.2014.10.011.
18. Bhalla A, Yehya N, Mack WJ, Wilson ML, Khemani RG, Newth CJL. The association between inhaled nitric oxide treatment and ICU mortality and 28-day ventilator-free days in pediatric acute respiratory distress syndrome. *Crit Care Med* 2018; 46: 1803-1810. DOI: 10.1097/CCM.0000000000003312.
19. Chandra S, Goel S, Dawra R. Early neuromuscular blockade in children with pediatric acute respiratory distress syndrome. *J Pediatr Intensive Care* 2020; 9: 201-206. DOI: 10.1055/s-0040-1708557.
20. Antalová N, Klučka J, Říhová M, Poláčková S, Pokorná A, Štourač P. Ventilator-associated pneumonia prevention in pediatric patients: narrative review. *Children (Basel)* 2022; 9: 1540. DOI: 10.3390/children9101540.
21. Taylor MA, Maldonado Y. Anesthetic management of patients on ECMO. In: *Extracorporeal Membrane Oxygenation: Advances in Therapy*. Firstenberg MS (ed.). London: InTech; 2016. DOI: 10.5772/63309.
22. Banfi C, Pozzi M, Siegenthaler N, Brunner ME, Tassaux D, Obadia JF, et al. Venovenous extracorporeal membrane oxygenation: cannulation techniques. *J Thorac Dis* 2016; 8: 3762-3773. DOI: 10.21037/jtd.2016.12.88.
23. Conrad SA, Grier LR, Scott LK, Green R, Jordan M. Percutaneous cannulation for extracorporeal membrane oxygenation by intensivists: a retrospective single-institution case series. *Crit Care Med* 2015; 43: 1010-1015. DOI: 10.1097/CCM.0000000000000883.
24. Platts DG, Sedgwick JF, Burstow DJ, Mullany DV, Fraser JF. The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation. *J Am Soc Echocardiogr* 2012; 25: 131-141. DOI: 10.1016/j.echo.2011.11.009.
25. Pavlushkov E, Berman M, Valchanov K. Cannulation techniques for extracorporeal life support. *Ann Transl Med* 2017; 5: 70. DOI: 10.21037/atm.2016.11.47.
26. Passariello M, Tarrant C. Psychological safety in an ECMO retrieval team: a qualitative study to inform improvement. *BMJ Open Qual* 2024; 13: e002706. DOI: 10.1136/bmjopen-2023-002706.
27. Labib A. Road transport on ECMO: the key elements. *Qatar Med J* 2017; 2017: 50. DOI: 10.5339/qmj.2017.swacelo.50.
28. Mojoli F, Bianzina S, Caneva L, Tavazzi G, Mongodi S, Pozzi M, et al. Temperature monitoring during ECMO: an in vitro study. *Intensive Care Med Exp* 2015; 3 (Suppl. 1): A506. DOI: 10.1186/2197-425X-3-S1-A506.
29. Bilodeau KS, Charette K, McMullan DM. Safety and efficacy of extracorporeal membrane oxygenation heating units. *World J Pediatr Congenit Heart Surg* 2023; 15: 30-35. DOI: 10.1177/21501351231185114.
30. Rypulak E, Szczukocka M, Czarnik T. Utilisation and outcomes of a mobile (ambulance and air transport) venovenous extracorporeal membrane oxygenation (VV-ECMO) program in Poland during the COVID-19 pandemic – a retrospective, two-centre, case-series study. *Anaesthesiol Intensive Ther* 2024; 56: 141-145. DOI: 10.5114/ait.2024.139526.
31. McMichael ABV, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. *ASAIO J* 2022; 68: 303-310. DOI: 10.1097/MAT.0000000000001652.
32. Alexander PMA, Bembea MM, Cashen K, Cheifetz IM, Dalton HJ, Himebauch AS, et al; PEACE, in collaboration with PALISI, BloodNet and PediECMO. Executive summary: the Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative (PEACE) Consensus Conference. *Pediatr Crit Care Med* 2024; 25: 643-675. DOI: 10.1097/PCC.0000000000003480.
33. Dabbous MK, Sakr FR, Malaeb DN. Anticoagulant therapy in pediatrics. *J Basic Clin Pharm* 2014; 5: 27-33. DOI: 10.4103/0976-0105.134947.
34. Chegondi M, Vijayakumar N, Totapally BR. Management of anticoagulation during extracorporeal membrane oxygenation in children. *Pediatr Rep* 2022; 14: 320-332. DOI: 10.3390/pediatric14030039.
35. Ozment C, Alexander PMA, Chandler W, Emami S, Hyslop R, Monagle P, et al; PEACE. Anticoagulation monitoring and targets: the Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative conference. *Pediatr Crit Care Med* 2024; 25 (7 Suppl 1): e14-e24. DOI: 10.1097/PCC.0000000000003494.
36. Rogerson CM, Hobson MJ. The heparin-antithrombin product: a novel value for pediatric extracorporeal anticoagulation. *J Extra Corpor Technol* 2022; 54: 115-122. DOI: 10.1182/ject-115-122.
37. Tume LN, Valla FV, Joosten K, Chaparro CJ, Latten L, Marino LV, et al. Nutritional support for children during critical illness: European Society of Pediatric and Neonatal Intensive Care (ESPNIC) metabolism, endocrine and nutrition section position statement and clinical recommendations. *Intensive Care Med* 2020; 46: 411-425. DOI: 10.1007/s00134-019-05922-5.
38. Mansour M, Knebusch N, Ontaneda A, Vazquez S, Daughtry J, Typko K, et al. Nutrition provision in pediatric extracorporeal membrane oxygenation: evidence, challenges, and clinical considerations. *Nutrients* 2025; 17: 1553. DOI: 10.3390/nu17091553.
39. Smith HAB, Besunder JB, Betters KA, Johnson PN, Srinivasan V, Stormorken A, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. *Pediatr Crit Care Med* 2022; 23: e74-e110. DOI: 10.1097/PCC.0000000000002873.
40. Rufener CR, Boullil Z, Suttner DM, Werho DK, Harvey HA, Bak EI, et al. Extubation practices and outcomes during pediatric respiratory extracorporeal membrane oxygenation: analysis of the Extracorporeal Life Support Organization Registry, 2018–2022. *Pediatr Crit Care Med* 2025; 26: e680-e688. DOI: 10.1097/PCC.0000000000003711.
41. Yoshida T, Uchiyama A, Matsuura N, Mashimo T, Fujino Y. Spontaneous breathing during lung-protective ventilation in an experimental acute lung injury model: high transpulmonary pressure associated with strong spontaneous breathing effort may worsen lung injury. *Crit Care Med* 2012; 40: 1578-1585. DOI: 10.1097/CCM.0b013e3182451c40.
42. Mallory PP, Selewski DT, Askenazi DJ, Cooper DS, Fleming GM, Paden ML, et al. Acute kidney injury, fluid overload, and outcomes in children supported with extracorporeal membrane oxygenation for a respiratory indication. *ASAIO J* 2020; 66: 319-326. DOI: 10.1097/MAT.0000000000001045.
43. Selewski DT, Cornell TT, Blatt NB, Han YY, Mottes T, Kommareddi M, et al. Fluid overload and fluid removal in pediatric patients on extracorporeal membrane oxygenation requiring continuous renal replacement therapy. *Crit Care Med* 2012; 40: 2694-2699. DOI: 10.1097/CCM.0b013e318258ff01.
44. Selewski DT, Askenazi DJ, Bridges BC, Cooper DS, Fleming GM, Paden ML, et al. The impact of fluid overload on outcomes in children treated with extracorporeal membrane oxygenation: a multicenter retrospective cohort study. *Pediatr Crit Care Med* 2017; 18: 1126-1135. DOI: 10.1097/PCC.0000000000001349.
45. Fleming GM, Sahay R, Zappitelli M, King E, Askenazi DJ, Bridges BC, et al. The incidence of acute kidney injury and its effect on neonatal and pediatric extracorporeal membrane oxygenation outcomes: a multicenter report from the Kidney Intervention During Extracorporeal Membrane Oxygenation Study Group. *Pediatr Crit Care Med* 2016; 17: 1157-1169. DOI: 10.1097/PCC.0000000000000970.
46. Goldstein SL, Currier H, Graf CD, Cosio CC, Brewer ED, Sachdeva R. Outcome in children receiving continuous venovenous hemofiltration. *Pediatrics* 2001; 107: 1309-1312. DOI: 10.1542/peds.107.6.1309.
47. Bridges BC, Dhar A, Ramanathan K, Steflik HJ, Schmidt M, Shekar K. Extracorporeal Life Support Organization guidelines for fluid overload, acute kidney injury, and electrolyte management. *ASAIO J* 2022; 68: 611-618. DOI: 10.1097/MAT.0000000000001702.
48. Maratta C, Potera RM, van Leeuwen G, Castillo Moya A, Raman L, Annich GM. Extracorporeal Life Support Organization (ELSO): 2020 pediatric respiratory ELSO guideline. *ASAIO J* 2020; 66: 975-979. DOI: 10.1097/MAT.0000000000001223.
49. Tonna JE, Boonstra PS, MacLaren G, Paden M, Brodie D, Anders M, et al. Extracorporeal Life Support Organization Registry international report 2022: 100,000 survivors. *ASAIO J* 2024; 70: 131-143. DOI: 10.1097/MAT.0000000000002128.
50. Tang W, Zhang W-T, Zhang J, Jiang KH, Ge YW, Zheng AB, et al. Prevalence of hematologic complications on extracorporeal membranous oxygenation in critically ill pediatric patients: a systematic review and meta-analysis. *Thromb Res* 2022; 222: 75-84. DOI: 10.1016/j.thromres.2022.12.014.
51. Dalton HJ, Cashen K, Reeder RW, Berg RA, Shanley TP, Newth CJL, et al. Hemolysis during pediatric extracorporeal membrane oxygenation: associations with circuitry, complications, and mortality. *Pediatr Crit Care Med* 2018; 19: 1067-1076. DOI: 10.1097/PCC.0000000000001709.
52. Zantek ND, Steiner ME, Teruya J, Baumann Kreuziger L, Raffini L, Muszynski JA, et al; PEACE. Recommendations on monitoring and replacement of antithrombin, fibrinogen, and von Willebrand factor in pediatric patients on extracorporeal membrane oxygenation: the Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative conference. *Pediatr Crit Care Med* 2024; 25 (7 Suppl 1): e35-e43. DOI: 10.1097/PCC.0000000000003492.

53. Rintoul NE, McMichael ABV, Bembea MM, DiGeronimo R, Patregnani J, Alexander PMA, et al; PEACE. Management of bleeding and thrombotic complications during pediatric extracorporeal membrane oxygenation: the Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative consensus conference. *Pediatr Crit Care Med* 2024; 25: e66-e77. DOI: 10.1097/PCC.0000000000003489.
54. Vajter J, Volod O. Anticoagulation management during ECMO: narrative review. *JHLT Open* 2025; 8: 100216. DOI: 10.1016/j.jhlto.2025.100216.
55. Strong AE, Rudolph K, Denburg MR, Badheka A. Hemolysis monitoring practices during extracorporeal membrane oxygenation: a survey report. *Blood Purif* 2025; 50: 30-34. DOI: 10.1159/000548469.
56. Lin G, Li Y, Zhuang Y, Fan Q, Luo Y, Zeng H. Seizures in children undergoing extracorporeal membrane oxygenation: a systematic review and meta-analysis. *Pediatr Res* 2023; 93: 755-762. DOI: 10.1038/s41390-022-02187-5.
57. Rosario DC, Ambati S. Extracorporeal membrane oxygenation in children. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025– (Last Update: 10 July 2023). Available at: <https://www.ncbi.nlm.nih.gov/books/NBK572104/> (Accessed: 12.02.2026).
58. Barbaro RP, Xu Y, Borasino S, Truempner EJ, Scott Watson R, Thiagarajan RR, et al. Does extracorporeal membrane oxygenation improve survival in pediatric acute respiratory failure? *Am J Respir Crit Care Med* 2018; 197: 1177-1186. DOI: 10.1164/rccm.201709-1893OC.
59. Erdil T, Lemme F, Konetzka A, Cavigelli-Brunner A, Niesse O, Dave H, et al. Extracorporeal membrane oxygenation support in pediatrics. *Ann Cardiothorac Surg* 2019; 8: 109-115. DOI: 10.21037/acs.2018.09.08.
60. Bishop MA, Moore A. Extracorporeal Membrane Oxygenation Weaning. 2023 Jun 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
61. Broman LM, Malfertheiner MV, Montisci A, Pappalardo F. Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. *J Thorac Dis* 2018; 10 (Suppl 5): S692-S697. DOI: 10.21037/jtd.2017.09.95.
62. Misselbrook GP, Kanji H, Thiara S, Ronco JJ, Kalan S, Chen L, et al. Prediction of successful veno-venous extracorporeal life support liberation using the oxygen challenge test. *Artif Organs* 2023; 47: 180-186. DOI: 10.1111/aor.14382.

Patient referral form for ECMO therapy

Patient identification

FULL NAME

SEX

DATE OF BIRTH

PESEL OR OTHER ID NUMBER

HEIGHT (CM)

WEIGHT (KG)

BMI

ADDRESS

Referring hospital

HOSPITAL (NAME, CITY)

WARD OR DEPARTMENT

REFERRING PHYSICIAN

24/7 PHONE

OFFICE PHONE

EMAIL

Family information and consent

Family or guardians informed of ECMO option

☐ Yes ☐ No

Informed consent obtained for data transfer and possible ECMO treatment

☐ Yes ☐ No

CONSENT GIVEN BY

DATE AND TIME

ECMO support type considered

- ☐ Respiratory failure (VV ECMO)
- ☐ Circulatory or cardiopulmonary failure (VA ECMO)

Diagnosis and disease course

PRIMARY DIAGNOSIS

COMORBID DIAGNOSES

SYMPTOM ONSET (DATE)

HOSPITAL ADMISSION (DATE)

ICU ADMISSION (DATE)

CURRENT PROBLEM (CAUSE OF RESPIRATORY OR CIRCULATORY FAILURE; TREATMENT TO DATE)

Respiratory and haemodynamic management

VENTILATION STARTED

Prone positioning trialed ☐ Yes ☐ No

Inhaled NO ☐ Yes ☐ No ☐ N/A

FIO₂

PEEP (CM H₂O)

TV (ML)

PIP (CM H₂O)

BRONCHODILATOR THERAPY

VASOPRESSORS OR INOTROPES

OTHER CIRCULATORY SUPPORT (IABP, LVAD)

Clinical state and comorbidities

NEUROLOGY (PUPILS, RECENT CT OR MRI)

CHEST X-RAY OR CT

ECHOCARDIOGRAPHY (EF)

CHRONIC DISEASE

ACTIVE BLEEDING (SITE)

Chronic renal failure ☐ Yes ☐ No

Acute renal failure ☐ Yes ☐ No

RRT MODALITY

ACTIVE INFECTION (SITE, PATHOGEN, ANTIMICROBIALS)

CARDIAC ARREST DURING THIS EPISODE (CPR DURATION, OUTCOME)

RECENT SURGERY OR TRAUMA

Laboratory parameters and arterial blood gases

DATE AND TIME OF RESULTS

PH	PACO ₂ mm Hg / kPa	PAO ₂ mm Hg / kPa	HCO ₃ ⁻ mmol/L	BE mmol/L	LACTATE mmol/L
HB g/dL / g/L	RBC ×10 ¹² /L	WBC ×10 ⁹ /L	PLT ×10 ⁹ /L	INR	APTT s
FIBRINOGEN g/L	CREATININEmg/dL / μmol/L	UREA mg/dL / mmol/L	UO PER H mL/kg/h	AST U/L	ALT U/L
GGT U/L	CRP mg/L	PCT ng/mL			

Inclusion criteria

PaO ₂ /FiO ₂ < 60 mm Hg for 3 h	☐ Yes ☐ No
PaO ₂ /FiO ₂ < 80 mm Hg for 6 h	☐ Yes ☐ No
OI > 40 for 6 h	☐ Yes ☐ No
No response to conventional ventilation	☐ Yes ☐ No
Prone positioning trialed	☐ Yes ☐ No
High-frequency ventilation trialed	☐ Yes ☐ No
Inhaled nitric oxide trialed	☐ Yes ☐ No
MAP > 20 to 25 cm H ₂ O	☐ Yes ☐ No
pH < 7.1	☐ Yes ☐ No

Contraindications

Irreversible disease process	☐ Yes ☐ No
Severe systemic disease	☐ Yes ☐ No
Lethal genetic syndrome	☐ Yes ☐ No
Intracranial haemorrhage (IVH grade 3 to 4)	☐ Yes ☐ No
Other contraindications to heparinisation	☐ Yes ☐ No
Mechanical ventilation > 14 days	☐ Yes ☐ No
Cannot apply lung-protective strategy	☐ Yes ☐ No

Notes and additional clinical information

Signature

REFERRING PHYSICIAN SIGNATURE

DATE AND TIME OF SUBMISSION

ABBREVIATIONS

ALT alanine aminotransferase aPTT activated partial thromboplastin time AST aspartate aminotransferase BE base excess BMI body mass index CPR cardiopulmonary resuscitation CRP C-reactive protein CT computed tomography ECMO extracorporeal membrane oxygenation EF ejection fraction FiO₂ fraction of inspired oxygen	GGT gamma-glutamyl transferase Hb haemoglobin HCO₃⁻ bicarbonate IABP intra-aortic balloon pump ICU intensive care unit INR international normalised ratio IVH intraventricular haemorrhage LVAD left ventricular assist device MAP mean airway pressure MRI magnetic resonance imaging N/A not available	NO nitric oxide OI oxygenation index, MAP × FiO ₂ × 100 / PaO ₂ PaCO₂ partial pressure of arterial carbon dioxide PaO₂ partial pressure of arterial oxygen PaO₂/FiO₂ ratio of arterial oxygen tension to inspired oxygen fraction PCT procalcitonin PEEP positive end-expiratory pressure PESEL Polish national identification number pH hydrogen-ion concentration PIP peak inspiratory pressure	PLT platelet count RBC red blood cell count RRT renal replacement therapy TV tidal volume UO urine output VA ECMO veno-arterial ECMO VV ECMO veno-venous ECMO WBC white blood cell count
--	---	--	---